- Home
- MGTX vs MGNX Comparison
MGTX vs MGNX Comparison
Compare MGTX & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- MGNX
- Stock Information
- Founded
- MGTX 2015
- MGNX 2000
- Country
- MGTX United States
- MGNX United States
- Employees
- MGTX N/A
- MGNX N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- MGNX Health Care
- Exchange
- MGTX Nasdaq
- MGNX Nasdaq
- Market Cap
- MGTX 520.8M
- MGNX 87.7M
- IPO Year
- MGTX N/A
- MGNX 2013
- Fundamental
- Price
- MGTX $6.61
- MGNX $1.24
- Analyst Decision
- MGTX Strong Buy
- MGNX Hold
- Analyst Count
- MGTX 2
- MGNX 9
- Target Price
- MGTX $24.00
- MGNX $5.33
- AVG Volume (30 Days)
- MGTX 448.5K
- MGNX 2.6M
- Earning Date
- MGTX 08-11-2025
- MGNX 08-05-2025
- Dividend Yield
- MGTX N/A
- MGNX N/A
- EPS Growth
- MGTX N/A
- MGNX N/A
- EPS
- MGTX N/A
- MGNX N/A
- Revenue
- MGTX $34,508,000.00
- MGNX $154,050,000.00
- Revenue This Year
- MGTX $365.04
- MGNX N/A
- Revenue Next Year
- MGTX $73.18
- MGNX N/A
- P/E Ratio
- MGTX N/A
- MGNX N/A
- Revenue Growth
- MGTX 203.23
- MGNX 255.31
- 52 Week Low
- MGTX $3.85
- MGNX $0.99
- 52 Week High
- MGTX $8.75
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- MGTX 59.61
- MGNX 38.61
- Support Level
- MGTX $6.07
- MGNX $1.26
- Resistance Level
- MGTX $6.80
- MGNX $1.41
- Average True Range (ATR)
- MGTX 0.37
- MGNX 0.17
- MACD
- MGTX 0.02
- MGNX -0.03
- Stochastic Oscillator
- MGTX 55.10
- MGNX 1.10
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.